THERAPY DOSSIER · th-2b94425af65a

Ultrafine silver nanoparticles of about 2 nm embedded in water-soluble gamma-cyclodextrin metal-organic frameworks, surface modified with GRGDS peptide

Device

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31069948 ↗2019Reported benefit

Ultrafine Silver Nanoparticles Embedded in Cyclodextrin Metal-Organic Frameworks with GRGDS Functionalization to Promote Antibacterial and Wound Healing Application.

RatWoundSprague-Dawley

Model: Skin wound with bacterial challenge; the specific wounding procedure is not described in the abstract

Template-guided synthesis in cyclodextrin metal-organic frameworks gave stable, aqueous-dispersible silver nanoparticles of about 2 nm with effective bacterial inhibition. GRGDS surface modification added a haemostatic effect that enhanced wound healing in synergy with the antibacterial action. No…

Extraction: extract · Supplied extraction confidence: 0.45. Machine-extracted fields require source verification.

Loading the evidence…